OrbiMed Capital GP VII LLC just bought $15.0M in ASPE. Track all SEC Form 4 insider trades in real-time.

San Carlos-based Dren Bio raised $350 million from a group including Lightspeed, 8VC, OrbiMed, and General Catalyst to push its rare blood cancer drug through late-stage clinical trials.

With OrbiMed’s largest ever Asian fund and TCG Crossover’s latest acquisition vehicle, investors see opportunities in the region’s healthcare sector.

Financing follows Incyte’s July 2026 acquisition of Star subsidiary Vega Therapeutics for up to $2 billion and builds on the Star team’s track record of creating and advancing innovative therapies Financing co-led by OrbiMed and Janus Henderson Investors, with participation from other leading healthcare investors SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital, and a leading sovereign wealth fund. Proceeds from the private financing will support Star’s next-generation pipeline of potential best-in-disease therapies, advancing its current preclinical programs into the clinic and expanding its pipeline with additional programs. “Our mission is to develop best-in-disease therapies at scale for the millions of patients with diseases of significant unmet need,” said Adam Rosenthal, Ph.D., founder and chief executive officer of Star Therapeutics. “This financing marks the next phase for Star, building on our...

OrbiMed has raised more $3 billion across two new private equity funds—including one specifically designed to support life science companies across Asia.

OrbiMed announces the successful raise of $3 billion for two private equity funds focused on the healthcare sector. This investment aims to drive innovation in life sciences.

OrbiMed raises $3B across two funds: $1.9B for US/Europe and $1B for Asia. Managing partner Carl Gordon cited AI and China's biopharma growth as key drivers.

OrbiMed, a leading healthcare investment firm, has successfully raised $3 billion for two new private equity funds focused on innovative healthcare.

OrbiMed announces a significant milestone, raising $3 billion across two private equity funds aimed at advancing healthcare innovation globally and in Asia.

OrbiMed has successfully raised $3 billion in commitments for two new private equity funds focused on healthcare investment, aiming to foster innovation in life sciences.

OrbiMed has raised $3 billion in commitments for two new private equity funds, targeting innovative healthcare solutions in Asia and globally.

Intellia stock hub: March 10, 2027 FDA date for lonvo-z, HAELO results, cash burn, OrbiMed debt, dilution and nex-z liver-safety risks.

Schedule 13D/A filed Oct 8. Who filed, the stake, and how it changed.

OrbiMed Genesis GP LLC just bought $10.0M in ADRX. Track all SEC Form 4 insider trades in real-time.

OrbiMed Genesis GP LLC just bought $1.0M in ADRX. Track all SEC Form 4 insider trades in real-time.

OrbiMed Genesis GP LLC just bought $5.1M in ADRX. Track all SEC Form 4 insider trades in real-time.

OrbiMed Genesis GP LLC just bought $15.0M in ETRA. Track all SEC Form 4 insider trades in real-time.

OrbiMed Genesis GP LLC just bought $5.0M in ETRA. Track all SEC Form 4 insider trades in real-time.